Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options — Overview, Diagnosis & Treatment Options | MyMedicPlus

Melanoma is a malignant tumor of melanocytes and the most dangerous form of skin cancer due to its high metastatic potential. Approximately 100,000 new cases and 8,000 deaths occur in the US annually. Most arise from skin (cutaneous melanoma, 90%), with rarer uveal (eye), mucosal, and acral subtypes. Rising incidence, particularly in young women, is strongly linked to UV exposure and tanning bed use. Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options to help patients understand the condition, its causes, symptoms, and available treatment options. This page provides evidence-based clinical information to help patients and caregivers understand this condition, its risk factors, symptoms, and available treatment options from accredited medical sources.

UV radiation from sunlight and tanning beds is the primary environmental carcinogen, inducing BRAF V600E and other somatic mutations. Risk factors include fair skin, blue or green eyes, red or blonde hair, multiple (greater than 50) common nevi, dysplastic nevus syndrome, family history of melanoma, prior melanoma, and immunosuppression. Germline mutations in CDKN2A, CDK4, BRCA2, BAP1, and TERT predispose to familial melanoma. The causes of Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

Early melanoma follows the ABCDE criteria: Asymmetry, irregular Border, Color variation (multiple shades), Diameter greater than 6 mm, and Evolution. Nodular melanoma appears as a rapidly growing, dark, raised nodule. Amelanotic melanoma is skin-colored, making detection difficult. Subungual melanoma presents as pigmented nail streaks (melanonychia) or nail destruction. Advanced disease causes palpable lymph nodes, skin nodules, and organ metastasis symptoms. Symptoms of Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

Dermoscopy enhances clinical detection accuracy. Excisional biopsy with 1-2 mm margins and histological assessment of Breslow thickness, Clark level, ulceration, mitotic rate, and microsatellitosis is mandatory. Sentinel lymph node biopsy (SLNB) is recommended for T1b (greater than 0.8 mm or ulcerated) and thicker tumors. BRAF V600 mutation testing is required for metastatic disease. AJCC 8th edition TNM staging incorporates Breslow thickness, ulceration, mitotic rate, and SLNB status. Diagnosis of Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Wide local excision with margins of 1-2 cm (based on Breslow thickness) is curative for localized disease. Adjuvant pembrolizumab or nivolumab reduces relapse risk in Stage IIB-III. Adjuvant dabrafenib plus trametinib for BRAF V600-mutant Stage III. Metastatic disease: first-line pembrolizumab or nivolumab plus ipilimumab (ORR 57%, long-term survival benefit) or BRAF-targeted therapy (dabrafenib plus trametinib, vemurafenib plus cobimetinib) for BRAF-mutant tumors. T-VEC (talimogene laherparepvec) for unresectable in-transit or Stage IIIB-IVM1a disease. Treatment of Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

Five-year survival by AJCC stage: Stage IA 98%, Stage IB 94%, Stage IIA 87%, Stage IIB 82%, Stage IIC 75%, Stage IIIA 93%, Stage IIIB 83%, Stage IIIC 69%, Stage IIID 32%, Stage IV 15-20% (historically). With modern immunotherapy, 5-year OS for Stage IV metastatic melanoma has improved to approximately 40-52% with nivolumab plus ipilimumab. BRAF-targeted therapy achieves 5-year OS of approximately 34%. The prognosis for Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

Daily use of broad-spectrum SPF 30 or higher sunscreen on exposed skin reduces melanoma risk. Protective clothing, wide-brimmed hats, and UV-protective sunglasses limit UV damage. Avoiding tanning beds completely eliminates tanning-bed-associated UV risk. Annual full-body skin examination by a dermatologist is recommended for high-risk individuals (personal or family history, atypical nevi, immunosuppression). Monthly self-skin examination with ABCDE criteria aids early detection. Genetic counseling for CDKN2A and other high-risk mutation carriers. Prevention strategies for Melanoma: Symptoms, ABCDE Criteria, and Modern Treatment Options focus on reducing modifiable risk factors and promoting overall health. Lifestyle interventions such as a balanced diet, regular physical activity, and avoidance of tobacco and excessive alcohol are beneficial. Routine screening and early detection are important where treatment is more effective at early stages.

Go to the ER immediately for sudden severe headache, focal neurological deficit, or new-onset seizure from brain metastases, or haemodynamic instability from a haemorrhagic visceral metastasis. See a dermatologist urgently — within 2 weeks — for any pigmented skin lesion meeting the ABCDE criteria: Asymmetry, irregular Border, Color variation (multiple shades), Diameter greater than 6 mm, or Evolution (any recent change in size, shape, or colour); any rapidly growing or bleeding skin lesion; or a new palpable lymph node adjacent to a skin lesion. Do not observe a suspicious lesion beyond 4 weeks. Annual full-body skin examinations by a dermatologist are recommended for all patients with prior melanoma, multiple atypical nevi, or family history. CDKN2A and CDK4 germline mutation carriers require specialist-directed surveillance.